NAUT - NASDAQ
Nautilus Biotechnology, Inc.
$2.58
-3.7%Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
At a Glance
Live Snapshotnaut
Total Assets
Last Annual Value
191.11M
3-Year CAGR
-18%
5-Year CAGR
18%
10-Year CAGR
3%
Nautilus Biotechnology, Inc. Competitors Analysis of Total Assets
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Nautilus Biotechnology, Inc. NASDAQ:NAUT | 191.11M | -14.5% | -13.7% | N/A | |
 Tenaya Therapeutics, Inc. NASDAQ:TNYA | 146.92M | -4.8% | -14.2% | N/A | |
 Zura Bio Limited NASDAQ:ZURA | 113.95M | 4.2% | -4.1% | N/A | |
 Humacyte, Inc. NASDAQ:HUMA | 116.37M | -3.2% | -16.5% | N/A | |
 Arcturus Therapeutics Holdings Inc. NASDAQ:ARCT | 271.15M | -14.2% | -7.1% | 18.1% | |
 Sagimet Biosciences Inc. NASDAQ:SGMT | 116.48M | 6.4% | 14.6% | N/A | |
 Immuneering Corporation NASDAQ:IMRX | 231.99M | 31.3% | 6.8% | N/A | |
 Agenus Inc. NASDAQ:AGEN | 226.80M | -10.3% | -13.4% | 3.7% | |
 Cognition Therapeutics, Inc. NASDAQ:CGTX | 48.39M | 11.2% | -3.9% | N/A | |
 Context Therapeutics Inc. NASDAQ:CNTX | 68.49M | 62.2% | 5.9% | N/A | |
 TuHURA Biosciences, Inc. NASDAQ:HURA | 27.35M | 84.4% | 33.7% | 13.2% |
Nautilus Biotechnology, Inc. Fair Value Envelope
Related Guides
Continue your NAUT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.